TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03321786

Intervention type: OTHER
Intervention: The University of Pennsylvania Smell Identification Test (UPSIT)
Description: This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets.

Intervention type: OTHER
Intervention: The University of Pennsylvania Smell Identification Test (UPSIT)
Description: This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets.
Study: NCT01506414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO in combination with Rituximab
Description: Rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (Day 1, 8, 15, 22). Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (Day 1-14).
Study: NCT00778752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid (Lenalidomide)
Description: 3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.~If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.~If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials.
Study: NCT01401426

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic vertical sleeve gastrectomy
Description: Laparoscopic vertical sleeve gastrectomy for the treatment of morbid obesity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic vertical sleeve gastrectomy
Description: Laparoscopic vertical sleeve gastrectomy
Study: NCT03421288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Day 1 q2w: 840 mg IV over 1 hour (4 cycles perioperative with FLOT) + Day 1 q3w: 1200 mg IV over 1 hour (8 additional cycles monotherapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Day 1 q2w: 2600 mg/m² IV over 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Day 1 q2w: 2600 mg/m² IV over 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calciumfolinat
Description: Day 1 q2w: 200 mg/m² IV over 1 hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calciumfolinat
Description: Day 1 q2w: 200 mg/m² IV over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Day 1 q2w: 85 mg/m² IV over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Day 1 q2w: 85 mg/m² IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Day 1 q2w: 50 mg/m² IV over 1 hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Day 1 q2w: 50 mg/m² IV over 1 hour
Study: NCT01073956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medium-wave 448 kHz therapy
Description: 0.5 MHz radiofrequency for 10 minutes. At SPS insertion and bicipital groove

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic therapy
Description: Pulsed 1 MHz ultrasound at 2 W/cm2 for 10 minutes. At SPS insertion and bicipital-groove

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive electrotherapy
Description: Inactive electrotherapy, inactive head, dosage 0 W/cm2 for 10 minutes. At SPS insertion and bicipital groove.
Study: NCT04097444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study: NCT01940159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SEP-363856
Description: SEP-36385625 as a single oral dose of 25, 50, 100, and 150 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose placebo
Study: NCT01942278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BHOMA
Description: A complex health systems, clinical care, and community intervention to improve outcomes
Study: NCT01919827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endobronchial infusion of adult mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells derived from bone marrow
Study: NCT02582554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NutriSTEP
Description: Provision of nutrition risk screening with NutriSTEP (a nutrition risk screening questionnaire for preschoolers) and nutrition education with NutriSTEP related materials
Study: NCT03709888

Intervention type: DRUG
Intervention: Memantine XR-pregabalin combination therapy
Description: Pregabalin and memantine XR work in different pathways and are approved by the U.S. Food and Drug Administration for various indications. Both medications have an established safety profile and have demonstrated improvement on neuropathy-related symptoms.
Study: NCT01572532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening treatment and referral
Description: Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.~Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days.
Study: NCT03699982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily calorie target based on resting energy expenditure
Description: Resting Energy Expenditure will be determined using the Harris-Benedict formula and indirect calorimetry testing. Additionally, a 48 Hour Dietary Recall will be completed to estimate approximate caloric intake at baseline.~Participants will be instructed to increase their daily calorie intake based on the highest REE/caloric intake, whether by indirect calorimetry, the Harris-Benedict formula, or patient's estimated current caloric intake.
Study: NCT04045613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg once daily monotherapy
Description: Derazantinib was administered orally at a dose of 300 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 200 mg once daily + atezolizumab 1200 mg
Description: Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg once daily+ atezolizumab 1200 mg
Description: Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 200 mg twice daily + atezolizumab 1200 mg
Description: Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg once daily monotherapy (QD)
Description: Derazantinib was administered orally at a dose of 300 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg once daily + atezolizumab 1200 mg
Description: Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 200 mg twice daily monotherapy
Description: Derazantinib was administered orally at a dose of 200 mg twice daily
Study: NCT01221467

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Overnight closed-loop
Description: The closed-loop system is purpose-built and comprises a hand-held computer containing the algorithm and communicating with the CGM device and the insulin pump.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Overnight closed-loop
Description: The closed-loop system is purpose-built and comprises a hand-held computer containing the algorithm and communicating with the CGM device and the insulin pump.
Study: NCT03300648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Description: Intubation and mechanical ventilation for a maximum of 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: Intravenous 3 percent hypertonic saline for a maximum of 7 days
Study: NCT02910375

Intervention type: OTHER
Group type: OTHER
Intervention: Cohort A
Description: Venous sampling (n=13) will be performed in the hospital at D0 (prior to first golimumab injection), D3, D7, D14 (prior to second injection), D28, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D3, M1D7, M2D0 (8 weeks after M0D0, week 14), M3D0 (12 weeks after M0D0, week 18) Dried blood spot sampling (n=39) will be performed at D0 (prior to first golimumab injection), D1, D2, D3, D4, D5, D6, D7, D10, D14, D15, D16, D17, D18, D19, D20, D21, D28, D35, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, rig week 14), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, week 18)

Intervention type: OTHER
Group type: OTHER
Intervention: Cohort B
Description: Venous sampling (n=8) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D3, M1D7, M2D0 (8 weeks after M0D0, right before next injection), M3D0 (12 weeks after M0D0, right before next injection) Dried blood spot sampling (n=20) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, right before next injection), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, right before next injection)
Study: NCT01098955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: 6 x 60-minute counseling sessions delivered over a 5-week period
Study: NCT04172987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/NGM
Description: Combination oral contraceptive administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/NGM
Description: Combination oral contraceptive administered orally
Study: NCT01098955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational and Behavioral Counseling
Description: 6 x 60-minute counseling sessions delivered over a 5-week period
Study: NCT00761774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.
Study: NCT01201564

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraperitoneal onlay mesh repair
Description: The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sublay mesh repair
Description: The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
Study: NCT01098955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 2 mg daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 2 mg daily for 12 weeks
Study: NCT02135601

Intervention type: OTHER
Group type: OTHER
Intervention: Water colonoscopy
Description: Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
Study: NCT02947763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mixture of metronidazole, ciprofloxacin, and minocycline
Description: placement of intracanal medication
Study: NCT04051593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical stabilization exercise
Description: The participants followed instructional videos and performed the cervical stabilization exercise program at home for 20 minutes/day, 3 days/week, for 6 weeks.
Study: NCT04651231

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: releasable sutures in punch trabeculectomy
Description: punch trabeculectomy,scleral flap suturing
Study: NCT03408873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abilify Maintena
Description: Drug is in an injectable form and will be administered approximately every four weeks through Week 24 of the study. Dosage is per package insert or at the discretion of the psychiatrist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement (CAE)
Description: CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
Study: NCT03225755

Intervention type: DRUG
Intervention: Growth hormone
Description: Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
Study: NCT04546412

Intervention type: DEVICE
Intervention: Vitrification and thawing
Description: Vitrification using the Cryotop® - Open System followed by thawing
Study: NCT02856776

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D provided in capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D provided in capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D provided in capsule form
Study: NCT04651231

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: releasable sutures in punch trabeculectomy
Description: punch trabeculectomy,scleral flap suturing
Study: NCT02932111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteopathic session
Description: 3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo manipulative session
Description: 3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
Study: NCT03498261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin has been commonly used as an adjuvant in the treatment of neuropathic pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study: NCT01989715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: analyzing the position of the body, muscle activity
Study: NCT02457598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously
Study: NCT03740165

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for olaparib
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for olaparib
Description: Oral tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion
Study: NCT01224561

Intervention type: BEHAVIORAL
Intervention: Lipid overnutrition
Description: During 4 months, the daily caloric intake will be increased by about 70 g fat as butter 20 grams, 100 grams of cheese (Emmental) and 40 grams of almonds. This overnutrition corresponds to an excess of 760 kcal / day or 21,280 calories for the period and then taken to a theoretical 2.4 kg of fat (1 kg fat = 9000 kcal).

Intervention type: BEHAVIORAL
Intervention: Lipid overnutrition
Description: During 4 months, the daily caloric intake will be increased by about 70 g fat as butter 20 grams, 100 grams of cheese (Emmental) and 40 grams of almonds. This overnutrition corresponds to an excess of 760 kcal / day or 21,280 calories for the period and then taken to a theoretical 2.4 kg of fat (1 kg fat = 9000 kcal).
Study: NCT01594476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUS
Description: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUS
Description: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device
Study: NCT02065869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 T cells
Description: 1x10E6 cells/kg infused on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: 0.4mg/kg administered IV to treat GVHD
Study: NCT00006386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Study: NCT01704781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
Study: NCT02856776

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D provided in capsule form
Study: NCT03113396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: baclofen oral, 10mg, tid for 2 weeks (or placebo, identically looking capsules) after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.